Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: MicroRNAs (miRNAs) post-transcriptionally regulate gene expression by targeting messenger RNAs. The expression of miRNAs was demonstrated to differ between patients with rheumatoid arthritis (RA) and healthy subjects. The aim of this study was to analyse cellular miRNAs from peripheral mononuclear cells (PBMCs) in order to determine their predictive value for achieving remission or low disease activity in patients with early RA.
Methods: At first, miRNAs were screened by TaqMan MicroRNA Array Cards in 4 treatment naïve patients with early RA (disease duration < 6 months) who achieved long-term remission (3 females; mean age 59 years; DAS28< 2.6) and 4 treatment naïve patients with early RA (disease duration < 6 months) with persistently high disease activity (3 females; mean age 63 years; DAS28> 5.1). Thirteen miRNAs with at least 2-fold difference between both groups were validated in a cohort of 60 patients (44 females; mean age 54 years) with early RA (baseline DAS28= 5.64, CRP= 22.72; DAS28 after 6 months= 2.80, CRP= 5.17); and 54 healthy controls (HC) (41 females; mean age 51 years). Total RNA was isolated from PBMCs in treatment naïve early RA patients at baseline and after the first and third month of conventional therapy. The expression of miRNAs was determined by quantitative PCR. Small nucleolar RNA RNU44 was used for normalization. Disease activity of RA patients was assessed according to the 28-Joint Count Disease Activity Score (DAS28) and the Simplified Disease Activity Index (SDAI). Area under the curve analysis was used to determine the predictive value of miRNAs to achieve remission or low disease activity.
Results: Cellular miRNA-31 expression was significantly lower in patients with early RA compared to HC (p= 0.002) and the therapy initiation contributed to its normalization over time. The expression of cellular miRNA-10a was also lower in patients with early RA compared to HC (p< 0.0001) however it has not significantly changed during the therapy. Although both miRNAs did not correlate with disease activity, higher baseline and also one-month miRNA-31 expression predicted achievement of remission after 6 months (DAS28: AUC= 0.713, p= 0.016; SDAI: AUC= 0.732, p= 0.011, and DAS28: AUC= 0.760, p= 0.003; SDAI: AUC= 0.734, p= 0.010; respectively). In addition, higher baseline expression of miRNA-10a predicted remission and low disease activity achievement after 12 months (DAS28: AUC= 0.750, p= 0.012; SDAI: AUC= 0.718, p= 0.038).
Conclusion: The expression of cellular miRNA-31 and miRNA-10a may represent potential biomarkers of treatment response in patients with early RA.
Acknowledgement: MHCR project no. 00023728, GAUK-367615 and SVV 260 373
To cite this abstract in AMA style:Hruskova V, Prajzlerova K, Komarc M, Vernerova L, Mann HF, Filkova M, Pavelka K, Vencovsky J, Senolt L. Baseline Expressions of Cellular microRNA-31 and microRNA-10a Predict Remission and Low Disease Activity in Patients with Early Rheumatoid Arthritis after Six and Twelve Months of Therapy [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/baseline-expressions-of-cellular-microrna-31-and-microrna-10a-predict-remission-and-low-disease-activity-in-patients-with-early-rheumatoid-arthritis-after-six-and-twelve-months-of-therapy/. Accessed July 1, 2022.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-expressions-of-cellular-microrna-31-and-microrna-10a-predict-remission-and-low-disease-activity-in-patients-with-early-rheumatoid-arthritis-after-six-and-twelve-months-of-therapy/